231 related articles for article (PubMed ID: 23180380)
1. P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model.
Ribeiro AS; Sousa B; Carreto L; Mendes N; Nobre AR; Ricardo S; Albergaria A; Cameselle-Teijeiro JF; Gerhard R; Söderberg O; Seruca R; Santos MA; Schmitt F; Paredes J
J Pathol; 2013 Apr; 229(5):705-18. PubMed ID: 23180380
[TBL] [Abstract][Full Text] [Related]
2. Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells.
Ribeiro AS; Albergaria A; Sousa B; Correia AL; Bracke M; Seruca R; Schmitt FC; Paredes J
Oncogene; 2010 Jan; 29(3):392-402. PubMed ID: 19901964
[TBL] [Abstract][Full Text] [Related]
3. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
Paredes J; Albergaria A; Oliveira JT; Jerónimo C; Milanezi F; Schmitt FC
Clin Cancer Res; 2005 Aug; 11(16):5869-77. PubMed ID: 16115928
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
6. Proteomics analysis of E-cadherin knockdown in epithelial breast cancer cells.
Vergara D; Simeone P; Latorre D; Cascione F; Leporatti S; Trerotola M; Giudetti AM; Capobianco L; Lunetti P; Rizzello A; Rinaldi R; Alberti S; Maffia M
J Biotechnol; 2015 May; 202():3-11. PubMed ID: 25449012
[TBL] [Abstract][Full Text] [Related]
7. [Claudins as prognostic factors of breast cancer].
Szász MA
Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
[TBL] [Abstract][Full Text] [Related]
8. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
9. ERβ1 inhibits the migration and invasion of breast cancer cells through upregulation of E-cadherin in a Id1-dependent manner.
Zhou Y; Ming J; Xu Y; Zhang Y; Jiang J
Biochem Biophys Res Commun; 2015 Feb; 457(2):141-7. PubMed ID: 25514034
[TBL] [Abstract][Full Text] [Related]
10. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis.
Hazan RB; Phillips GR; Qiao RF; Norton L; Aaronson SA
J Cell Biol; 2000 Feb; 148(4):779-90. PubMed ID: 10684258
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer.
Gonzalez MA; Pinder SE; Wencyk PM; Bell JA; Elston CW; Nicholson RI; Robertson JF; Blamey RW; Ellis IO
J Pathol; 1999 Apr; 187(5):523-9. PubMed ID: 10398116
[TBL] [Abstract][Full Text] [Related]
12. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.
Pinho SS; Matos AJ; Lopes C; Marcos NT; Carvalheira J; Reis CA; Gärtner F
BMC Cancer; 2007 Jul; 7():124. PubMed ID: 17617904
[TBL] [Abstract][Full Text] [Related]
13. P-cadherin role in normal breast development and cancer.
Albergaria A; Ribeiro AS; Vieira AF; Sousa B; Nobre AR; Seruca R; Schmitt F; Paredes J
Int J Dev Biol; 2011; 55(7-9):811-22. PubMed ID: 22161837
[TBL] [Abstract][Full Text] [Related]
14. HS3ST2 modulates breast cancer cell invasiveness via MAP kinase- and Tcf4 (Tcf7l2)-dependent regulation of protease and cadherin expression.
Vijaya Kumar A; Salem Gassar E; Spillmann D; Stock C; Sen YP; Zhang T; Van Kuppevelt TH; Hülsewig C; Koszlowski EO; Pavao MS; Ibrahim SA; Poeter M; Rescher U; Kiesel L; Koduru S; Yip GW; Götte M
Int J Cancer; 2014 Dec; 135(11):2579-92. PubMed ID: 24752740
[TBL] [Abstract][Full Text] [Related]
15. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer.
Yoshida R; Kimura N; Harada Y; Ohuchi N
Int J Oncol; 2001 Mar; 18(3):513-20. PubMed ID: 11179480
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia activates cadherin-22 synthesis via eIF4E2 to drive cancer cell migration, invasion and adhesion.
Kelly NJ; Varga JFA; Specker EJ; Romeo CM; Coomber BL; Uniacke J
Oncogene; 2018 Feb; 37(5):651-662. PubMed ID: 28991229
[TBL] [Abstract][Full Text] [Related]
17. SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells.
Ribeiro AS; Nobre AR; Mendes N; Almeida J; Vieira AF; Sousa B; Carvalho FA; Monteiro J; Polónia A; Fonseca M; Sanches JM; Santos NC; Seruca R; Paredes J
Cell Commun Signal; 2018 Nov; 16(1):75. PubMed ID: 30404626
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival.
Guriec N; Marcellin L; Gairard B; Caldéroli H; Wilk A; Renaud R; Bergerat JP; Oberling F
Invasion Metastasis; 1996; 16(1):19-26. PubMed ID: 8830762
[TBL] [Abstract][Full Text] [Related]
19. The bacterial protein azurin impairs invasion and FAK/Src signaling in P-cadherin-overexpressing breast cancer cell models.
Bernardes N; Ribeiro AS; Abreu S; Mota B; Matos RG; Arraiano CM; Seruca R; Paredes J; Fialho AM
PLoS One; 2013; 8(7):e69023. PubMed ID: 23894398
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
